Comprehensive guide to Wharton's jelly mesenchymal stem cells — sourcing, biology, clinical applications, safety, dosing, and treatment availability in Turkey.
Wharton's jelly stem cells are neonatal mesenchymal stem cells sourced from the connective tissue of the umbilical cord. They are more potent, more proliferative, and more immune-privileged than adult bone marrow or adipose MSCs — making them the gold standard for allogeneic regenerative therapy.
Frequently Asked Questions
What is Wharton's jelly?
Wharton's jelly is the gelatinous connective tissue that cushions and surrounds the two arteries and one vein inside the human umbilical cord. It is made primarily of mucopolysaccharides — hyaluronic acid and chondroitin sulfate — together with collagen fibers and a uniquely rich population of mesenchymal stem cells. It was first described by the English physician Thomas Wharton in 1656.
What is Wharton's jelly made of?
Wharton's jelly is composed of a hydrated proteoglycan matrix (mainly hyaluronic acid and chondroitin sulfate), collagen types I, III and VI, fibroblast-like stromal cells, and a high-density population of mesenchymal stem cells (MSCs). This matrix gives the umbilical cord its springy, gel-like texture and protects the cord vessels from compression during pregnancy.
What is the function of Wharton's jelly?
Biologically, Wharton's jelly protects the umbilical cord vessels from kinking and compression, regulates blood flow to the fetus, and serves as a reservoir of stem and progenitor cells. In regenerative medicine, the same tissue is processed to isolate Wharton's jelly mesenchymal stem cells (WJ-MSCs), which are used clinically for their anti-inflammatory and tissue-supportive paracrine signaling.
Where is Wharton's jelly found?
Wharton's jelly is found exclusively inside the umbilical cord, between the umbilical vessels and the outer amniotic epithelium. It is not present in the placenta or in adult tissues — its availability is limited to the moment of birth, which is why ethically collected umbilical cords are the only source of true WJ-MSCs.
What are Wharton's jelly stem cells?
Wharton's jelly stem cells are mesenchymal stem cells (MSCs) sourced from Wharton's jelly — the gelatinous connective tissue surrounding the blood vessels of the umbilical cord. They are ethically collected after healthy, full-term births with informed maternal consent. Wharton's jelly MSCs (WJ-MSCs) are considered among the most potent and proliferative MSC populations available for clinical use.
Why are Wharton's jelly stem cells preferred over adult stem cells?
WJ-MSCs offer several advantages over bone-marrow– or adipose-derived adult MSCs: (1) they are neonatal cells with longer telomeres and stronger proliferative capacity, (2) they have superior anti-inflammatory and immunomodulatory properties, (3) they are immunologically privileged (low HLA-II expression) making them safe for allogeneic use without HLA matching, (4) they are collected non-invasively from material that would otherwise be discarded, and (5) they can be banked, expanded, and dose-standardized in GMP laboratories.
Is Wharton's jelly FDA approved?
In the United States, Wharton's jelly–derived mesenchymal stem cell injections are not FDA-approved as a drug. The FDA has issued guidance that minimally manipulated, homologous-use cord-tissue products fall under Section 361 of the PHS Act, while expanded MSC products are regulated as biologic drugs requiring an Investigational New Drug (IND) application. Turkey regulates the same cells under Ministry of Health licensing, which is why international patients travel to Istanbul for treatment.
Is Wharton's jelly safe?
WJ-MSCs have an excellent published safety profile across hundreds of clinical studies. Because they are immunologically privileged, allogeneic use does not require HLA matching or immunosuppression. Common transient effects include mild low-grade fever or fatigue lasting 24–48 hours. Serious adverse events are extremely rare when cells are sourced and processed in GMP-certified facilities such as those used by TurkeyStemcell.
How to increase Wharton's jelly?
Wharton's jelly content inside the umbilical cord can only be influenced during pregnancy — primarily through maternal nutrition, hydration and avoidance of smoking. Once the cord is delivered, the amount of Wharton's jelly is fixed. For patients, what matters clinically is not 'increasing' Wharton's jelly but receiving a properly dosed, GMP-characterized WJ-MSC product.
Does Wharton's jelly contain live stem cells?
Yes. Fresh Wharton's jelly contains a viable, adherent population of mesenchymal stem cells. After GMP processing and controlled cryopreservation, cell viability of ≥90% is routinely maintained at the time of clinical administration.
Are Wharton's jelly stem cells ethical?
Yes. Wharton's jelly is part of the umbilical cord, which is routinely discarded after delivery. Collection requires no harm to mother or newborn and is performed only with informed maternal consent at the time of birth. There are no embryonic, fetal, or invasive sourcing concerns — these are post-natal, ethically harvested cells.
What conditions are Wharton's jelly stem cells used for?
Clinical and translational research supports the use of WJ-MSCs across neurological conditions (multiple sclerosis, Parkinson's disease, ALS, stroke recovery, TBI, spinal cord injury, cerebral palsy, autism support), orthopedic conditions (knee osteoarthritis, joint cartilage support), autoimmune conditions (rheumatoid arthritis, lupus, Crohn's disease), pulmonary conditions (COPD), endocrine support (Type 1 and Type 2 diabetes), and anti-aging and wellness protocols.
How are Wharton's jelly stem cells administered?
Routes of administration are selected based on the clinical target: intravenous (IV) infusion for systemic conditions, intrathecal injection (via lumbar puncture) for central nervous system targeting, intra-articular injection for joints, and localized injection for site-specific tissue support. Many advanced protocols combine multiple routes within a single program.
What is the typical dose of Wharton's jelly MSCs?
Clinical doses are typically expressed as cells-per-kilogram body weight (cells/kg) or total cell count. Most protocols deliver 1–2 million viable WJ-MSCs per kilogram body weight per session, equivalent to approximately 70–200 million cells per adult patient. Your specialist will recommend the precise dose based on indication, body weight, and route of administration.
How are Wharton's jelly stem cells processed in the laboratory?
After ethical collection, the umbilical cord is transported under cold chain to a GMP-certified laboratory. Wharton's jelly is dissected, enzymatically digested, and MSCs are isolated through a standardized adherence and expansion protocol. Each batch undergoes quality control: viability (≥90%), identity (CD73+/CD90+/CD105+ and CD34−/CD45− surface markers), sterility (USP ), endotoxin (USP ), mycoplasma testing, and karyotype stability.
How much do Wharton's jelly stem cell injections cost?
Wharton's jelly MSC programs at TurkeyStemcell range from approximately $5,900 (single-session anti-aging IV) to $22,000 (multi-day combined neurological program). Equivalent Wharton's jelly stem cell injections in the United States typically range from $15,000 to $40,000 per session, when available. See our stem cell therapy cost page for a full breakdown.
Where can I receive Wharton's jelly stem cell therapy?
TurkeyStemcell operates a fully equipped regenerative medicine clinic in Istanbul, Turkey, serving international patients from 40+ countries. Our facility includes GMP-certified cell processing, specialist consultation, multilingual care coordination, and structured remote follow-up. Book a free consultation to receive a personalized protocol recommendation.